-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On Corcept Therapeutics with Neutral Rating, Announces Price Target of $95

Benzinga·12/16/2025 13:39:53
Listen to the news
UBS analyst Ashwani Verma initiates coverage on Corcept Therapeutics (NASDAQ:CORT) with a Neutral rating and announces Price Target of $95.